Skip to content

Efficacy and safety of oral mannitol solution and polyethylene glycol electrolyte powder for bowel preparation before cold resection of colorectal polyps with diameter < 10mm: a national multicenter randomized controlled trial

Efficacy and safety of oral mannitol solution and polyethylene glycol electrolyte powder for bowel preparation before cold resection of colorectal polyps with diameter < 10mm: a national multicenter randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104100
Enrollment
Unknown
Registered
2025-06-11
Start date
2025-07-30
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal polyp

Interventions

Group A:The trial drug mannitol solution was administered orally before surgery
Group B:The control drug compound polyethylene glycol electrolyte powder was taken orally before surgery

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Participants aged between 18 and 80 years; 2.One or more non-cancerous colorectal polyps with a diameter of < 10mm were diagnosed preoperatively, and cold resection of colorectal polyps was planned in each research center; 3.Voluntarily participated in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to the investigational drug and its components; 2. Participants with any polyp removed by HSP and/or EMR; 3. Participating in other clinical trials or receiving special drug treatment; 4. Known or suspected gastrointestinal bleeding, gastrointestinal perforation or gastrointestinal obstruction; 5. Ascites, suspicious electrolyte abnormalities or uncorrected dehydration; 6. Presence or high suspicion of colorectal cancer, inflammatory bowel disease, toxic colitis or toxic megacolon; 7. Previous colorectal resection; 8. Known severe renal insufficiency, severe hepatic insufficiency, or severe congestive heart failure; participants with severe cardio-cerebrovascular, metabolic, endocrine and other diseases could not tolerate the examination; 10. (Prepare) pregnant or lactating women; 11. Constipation (defecation frequency <3 times per week, difficult and laborious defecation, dry stool, less volume, and more than 3 months).

Design outcomes

Primary

MeasureTime frame
Qualification rate of intestinal preparation;

Secondary

MeasureTime frame
Security (eg. Adverse reactions of bowel cleansing solution, Incidence of adverse events related to cold resection);Acceptability;Obedience (including indicators such as the proportion of patients who ingested the bowel preparation agent and the proportion who successfully completed bowel preparation);Cecal intubation rate;Colonoscopy procedure time;

Countries

China

Contacts

Public ContactBing Hu

West China Hospital, Sichuan University

hubing@wchscu.edu.cn+86 189 8060 1278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026